ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag biobusiness pharma business fda

Roche Buys Biotech for $8.3B
Jef Akst | Aug 27, 2014 | 1 min read
The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.
23andMe Enters Drug Development
Kerry Grens | Mar 12, 2015 | 2 min read
The personal genomics firm announces plans to make medicines.
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019 | 9 min read
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
Accessing Drugs for Medical Aid-in-Dying
Catherine Offord | Aug 16, 2017 | 9 min read
A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.
Banking on iPSCs
Kerry Grens | Sep 1, 2014 | 5 min read
A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.
Banking on iPSCs
Kerry Grens | Jun 29, 2014 | 6 min read
A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.
Cannabis Biotech
Daniel Cossins | Dec 1, 2014 | 8 min read
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
Brain cells with electrical firing. 3D rendering.
Microglia as Therapeutic Targets in Neurodegenerative Diseases
Sruthi S. Balakrishnan | Oct 1, 2021 | 10+ min read
Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Biopharma Looks to the Netherlands as European Hub
Jef Akst | Feb 1, 2021 | 7 min read
The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.

Run a Search

ADVERTISEMENT